These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11487715)

  • 1. Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel.
    Malingré MM; Ten Bokkel Huinink WW; Duchin K; Schellens JH; Beijnen JH
    Anticancer Drugs; 2001 Aug; 12(7):591-3. PubMed ID: 11487715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
    Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of oral paclitaxel.
    Malingré MM; Terwogt JM; Beijnen JH; Rosing H; Koopman FJ; van Tellingen O; Duchin K; Huinink WW; Swart M; Lieverst J; Schellens JH
    J Clin Oncol; 2000 Jun; 18(12):2468-75. PubMed ID: 10856107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
    Meerum Terwogt JM; Malingré MM; Beijnen JH; ten Bokkel Huinink WW; Rosing H; Koopman FJ; van Tellingen O; Swart M; Schellens JH
    Clin Cancer Res; 1999 Nov; 5(11):3379-84. PubMed ID: 10589748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
    Malingré MM; Beijnen JH; Rosing H; Koopman FJ; van Tellingen O; Duchin K; Ten Bokkel Huinink WW; Swart M; Lieverst J; Schellens JH
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):347-54. PubMed ID: 11345652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel.
    Malingré MM; Ten Bokkel Huinink WW; Mackay M; Schellens JH; Beijnen JH
    Eur J Clin Pharmacol; 2001 Jul; 57(4):305-7. PubMed ID: 11549208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
    Veltkamp SA; Alderden-Los C; Sharma A; Rosing H; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):43-50. PubMed ID: 16680462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients.
    Chu Z; Chen JS; Liau CT; Wang HM; Lin YC; Yang MH; Chen PM; Gardner ER; Figg WD; Sparreboom A
    Anticancer Drugs; 2008 Mar; 19(3):275-81. PubMed ID: 18510173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.
    Malingré MM; Beijnen JH; Rosing H; Koopman FJ; van Tellingen O; Duchin K; ten Bokkel Huinink WW; Swart M; Lieverst J; Schellens JH
    Anticancer Drugs; 2001 Apr; 12(4):351-8. PubMed ID: 11335792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration.
    Malingré MM; Schellens JH; van Tellingen O; Rosing H; Koopman FJ; Duchin K; Huinink WW; Swart M; Beijnen JH
    Anticancer Drugs; 2000 Nov; 11(10):813-20. PubMed ID: 11142688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.
    Kruijtzer CM; Boot H; Beijnen JH; Lochs HL; Parnis FX; Planting AS; Pelgrims JM; Williams R; Mathôt RA; Rosing H; Schot ME; Van Tinteren H; Schellens JH
    Ann Oncol; 2003 Feb; 14(2):197-204. PubMed ID: 12562644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
    Malingré MM; Beijnen JH; Rosing H; Koopman FJ; Jewell RC; Paul EM; Ten Bokkel Huinink WW; Schellens JH
    Br J Cancer; 2001 Jan; 84(1):42-7. PubMed ID: 11139311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
    Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
    Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-administration of cyclosporin enables oral therapy with paclitaxel.
    Meerum Terwogt JM; Beijnen JH; ten Bokkel Huinink WW; Rosing H; Schellens JH
    Lancet; 1998 Jul; 352(9124):285. PubMed ID: 9690410
    [No Abstract]   [Full Text] [Related]  

  • 15. A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.
    Veltkamp SA; Thijssen B; Garrigue JS; Lambert G; Lallemand F; Binlich F; Huitema AD; Nuijen B; Nol A; Beijnen JH; Schellens JH
    Br J Cancer; 2006 Sep; 95(6):729-34. PubMed ID: 16926835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors.
    Yang S; Gursoy RN; Lambert G; Benita S
    Pharm Res; 2004 Feb; 21(2):261-70. PubMed ID: 15032307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
    Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
    Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.
    van Asperen J; van Tellingen O; van der Valk MA; Rozenhart M; Beijnen JH
    Clin Cancer Res; 1998 Oct; 4(10):2293-7. PubMed ID: 9796957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
    Schädeli F; Marti HP; Frey FJ; Uehlinger DE
    Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.
    Kruijtzer CM; Schellens JH; Mezger J; Scheulen ME; Keilholz U; Beijnen JH; Rosing H; Mathôt RA; Marcus S; van Tinteren H; Baas P
    J Clin Oncol; 2002 Dec; 20(23):4508-16. PubMed ID: 12454106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.